Table of Contents 
ISRN Gastroenterology
Volume 2014 (2014), Article ID 245329, 11 pages
http://dx.doi.org/10.1155/2014/245329
Clinical Study

Preliminary Study on the Expression and the Clinical Significance of CD133 in Peripheral Blood of Patients with Gastric Adenocarcinoma

Ju-gang Wu, Ji-wei Yu, Rui-qi Lu, Shou-lian Wang, Xiao-chun Ni, Lin-hai Zheng, and Bo-jian Jiang

1st Department of General Surgery, Shanghai 3rd People’s Hospital, School of Medicine, Shanghai Jiao-Tong University, No. 280 Mohe Road, Shanghai 201900, China

Received 12 November 2013; Accepted 17 December 2013; Published 6 February 2014

Academic Editors: L. David, A. J. Karayiannakis, and J. Yu

Copyright © 2014 Ju-gang Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA: Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. H. D. Hemmati, I. Nakano, J. A. Lazareff et al., “Cancerous stem cells can arise from pediatric brain tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 15178–15183, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. A. T. Collins, P. A. Berry, C. Hyde, M. J. Stower, and N. J. Maitland, “Prospective identification of tumorigenic prostate cancer stem cells,” Cancer Research, vol. 65, no. 23, pp. 10946–10951, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. C. A. O'Brien, A. Pollett, S. Gallinger, and J. E. Dick, “A human colon cancer cell capable of initiating tumour growth in immunodeficient mice,” Nature, vol. 445, no. 7123, pp. 106–110, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Saigusa, K. Tanaka, Y. Toiyama et al., “Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy,” Annals of Surgical Oncology, vol. 16, no. 12, pp. 3488–3498, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Yasuda, K. Tanaka, S. Saigusa et al., “Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer,” Oncology Reports, vol. 22, no. 4, pp. 709–717, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Saigusa, K. Tanaka, Y. Toiyama et al., “Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer,” Oncology Reports, vol. 24, no. 2, pp. 345–350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Spring, T. Schüler, B. Arnold, G. J. Hämmerling, and R. Ganss, “Chemokines direct endothelial progenitors into tumor neovessels,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 50, pp. 18111–18116, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Peichev, A. J. Naiyer, D. Pereira et al., “Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors,” Blood, vol. 95, no. 3, pp. 952–958, 2000. View at Google Scholar · View at Scopus
  10. S. Rafii, D. Lyden, R. Benezra, K. Hattori, and B. Heissig, “Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?” Nature Reviews Cancer, vol. 2, no. 11, pp. 826–835, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. B. A. Peters, L. A. Diaz Jr., K. Polyak et al., “Contribution of bone marrow-derived endothelial cells to human tumor vasculature,” Nature Medicine, vol. 11, no. 3, pp. 261–262, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Dome, J. Timar, J. Dobos et al., “Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer,” Cancer Research, vol. 66, no. 14, pp. 7341–7347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Fürstenberger, R. Von Moos, R. Lucas et al., “Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer,” British Journal of Cancer, vol. 94, no. 4, pp. 524–531, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. D. G. Duda, K. S. Cohen, E. di Tomaso et al., “Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy,” Journal of Clinical Oncology, vol. 24, no. 9, pp. 1449–1453, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Boegl and C. Prinz, “CD133 expression in different stages of gastric adenocarcinoma,” British Journal of Cancer, vol. 100, no. 8, pp. 1365–1366, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. J.-W. Yu, P. Zhang, J.-G. Wu et al., “Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma,” Journal of Experimental and Clinical Cancer Research, vol. 29, no. 1, article 141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Ishigami, S. Ueno, T. Arigami et al., “Prognostic impact of CD133 expression in gastric carcinoma,” Anticancer Research, vol. 30, no. 6, pp. 2453–2457, 2010. View at Google Scholar · View at Scopus
  18. K. Hibi, M. Sakata, Y.-H. Kitamura et al., “Demethylation of the CD133 gene is frequently detected in early gastric carcinoma,” Anticancer Research, vol. 30, no. 4, pp. 1201–1203, 2010. View at Google Scholar · View at Scopus
  19. L. M. Smith, A. Nesterova, M. C. Ryan et al., “CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers,” British Journal of Cancer, vol. 99, no. 1, pp. 100–109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Wen, X. Z. Chen, K. Yang et al., “Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review,” PLoS ONE, vol. 8, no. 3, Article ID e59154, 2013. View at Publisher · View at Google Scholar
  21. Y. Wakamatsu, N. Sakamoto, H. Z. Oo et al., “Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer,” Pathology International, vol. 62, no. 2, pp. 112–119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Sano and Y. Kodera, “Japanese classification of gastric carcinoma: 3rd English edition,” Gastric Cancer, vol. 14, no. 2, pp. 101–112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J.-W. Yu, J.-G. Wu, Y. Tajima et al., “Study on lymph node metastasis correlated to lymphangiogenesis, lymphatic vessel invasion, and lymph node micrometastasis in gastric cancer,” Journal of Surgical Research, vol. 168, no. 2, pp. 188–196, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. J.-W. Yu, J.-G. Wu, L.-H. Zheng et al., “Influencing factors and clinical significance of the metastatic lymph nodes ratio in gastric adenocarcinoma,” Journal of Experimental and Clinical Cancer Research, vol. 28, no. 1, article 55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. R. Siewert, K. Böttcher, H. J. Stein, and J. D. Roder, “Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer study,” Annals of Surgery, vol. 228, no. 4, pp. 449–461, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Mehra, M. Penning, J. Maas et al., “Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases,” Clinical Cancer Research, vol. 12, no. 16, pp. 4859–4866, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. E. H. Lin, M. Hassan, Y. Li et al., “Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence,” Cancer, vol. 110, no. 3, pp. 534–542, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Iinuma, T. Watanabe, K. Mimori et al., “Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with dukes' stage B and C colorectal cancer,” Journal of Clinical Oncology, vol. 29, no. 12, pp. 1547–1555, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Nakamura, H. Iinuma, Y. Aoyagi, H. Shibuya, and T. Watanabe, “Predictive value of cancer stem-like cells and cancer-associated genetic markers for peritoneal recurrence of colorectal cancer in patients after curative surgery,” Oncology, vol. 78, no. 5-6, pp. 309–315, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Wu, J. Chen, J. Yu, S. Gao, and H. Shen, “A practical scoring system based upon ROC analysis for evaluating potential lymph nodes metastasis during gastric surgery,” Journal of Surgical Oncology, vol. 93, no. 7, pp. 534–540, 2006. View at Publisher · View at Google Scholar · View at Scopus